Nancy A. Thornberry's most recent trade in Schrodinger Inc was a trade of 9,341 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Schrodinger Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 9,341 | 9,341 | - | - | Stock Option (right to buy) | |
| Schrodinger Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 5,997 | 17,247 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 18,111 | 18,111 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 6,037 | 24,717 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 1,199 | 1,199 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 398 | 2,035 (0%) | 0% | 0 | Common Stock | |
| Schrodinger Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 8,550 | 8,550 | - | - | Stock Option (right to buy) | |
| Schrodinger Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 5,000 | 11,250 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,901 | 17,901 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 5,967 | 18,680 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,571 | 1,571 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Nancy A. Thornberry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 501 | 1,637 (0%) | 0% | 0 | Common Stock |